Thế Giới

US reconsiders Pfizer’s COVID-19 drug Paxlovid for lower-risk patients

Pfizer’s Paxlovid antiviral drug. (Photo: Reuters)

The move comes after the US public health agency warned that COVID-19 symptoms could return after people complete a course of use. Paxlovid drugand then they will have to quarantine a second time.

Dr Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, said: “For people who are really not at risk, I would advise against taking Paxlovid.”

The use of Pfizer’s Paxlovid, which is licensed to treat people with early-stage COVID-19 infections to prevent its progression, has skyrocketed, as the number of cases has increased. More than 162,000 courses were issued last week, compared with an average of 33,000 courses in a week since the drug hit the market in late 2021, according to US government data. promote the widespread use of the drug Paxlovid, which is purchased and distributed free of charge by the Government of this country.

However, increased use of Paxlovid has also emerged, with many people reporting that previously relieved symptoms reappeared a few days after finishing a 5-day course of Paxlovid.

US reconsiders Pfizer's COVID-19 drug Paxlovid for lower-risk patients - Photo 1.

Use of Pfizer’s Paxlovid drug has skyrocketed in the past week in the US. (Image: Reuters)

On May 24, the US Centers for Disease Control and Prevention cited reports about the above situation with concerns that patients COVID-19 reoccurrence can spread the virus, has advised that Paxlovid users should be isolated for the next five days if symptoms reappear.

Dr Bruce Farber, Northwell Health’s Head of Public Health and Epidemiology, said: “I don’t want to prescribe Paxlovid to people who are very low risk and not seriously ill, especially those who are very sick. who received the basic vaccine and the booster shot”. He said he still recommends Paxlovid for people with serious health conditions or over the age of 75.

Pfizer said it is monitoring the data, but believes that cases of COVID-19 reinfection are uncommon and that the cause is not solely related to Paxlovid. A Pfizer representative said: “We have not recorded any cases of drug resistance to date in patients treated with Paxlovid.”

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!

You are reading the article US reconsiders Pfizer’s COVID-19 drug Paxlovid for lower-risk patients
at Blogtuan.info – Source: vtv.vn – Read the original article here

Back to top button